MedTrace Logo

A Study of Revaree Plus in People With Breast Cancer

NCT07042581 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-02-06

No results posted yet for this study

Summary

The purpose of this study is to find out whether Revaree Plus is effective at improving vaginal health for people who are having symptoms of vaginal dryness during breast cancer treatment.

Conditions

  • Breast Cancer
  • Stage 0 Breast Cancer
  • Stage I Breast Cancer
  • Stage II Breast Cancer
  • Stage III Breast Cancer
  • Stage 0 Breast Carcinoma
  • Stage II Breast Carcinoma
  • Stage III Breast Carcinoma
  • Hormone-receptor-positive Breast Cancer
  • Hormone Receptor Positive Breast Carcinoma
  • Hormone Receptor Positive Malignant Neoplasm of Breast

Interventions

DRUG

Revaree Plus

Revaree Plus is a hyaluronic acid vaginal suppository

Sponsors & Collaborators

Principal Investigators

  • Shari Goldfarb, MD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-20
Primary Completion
2029-06-20
Completion
2029-06-20
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07042581 on ClinicalTrials.gov